IMPLANET Announces 2024 Full-Year Revenue Up 26% to €9.4 Million

• Continued acceleration in quarterly revenue growth since Q2 2024, with Q4 2024 reaching nearly €3.0 million, up 81% versus 2023
• Strong full-year performance in the medical equipment distribution business, generating €2.3 million in revenue

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its full-year 2024 revenue and cash position as of December 31, 2024.

Ludovic Lastennet, IMPLANET’s Chief Executive Officer, stated: “The strong commercial performance achieved in the second half of 2024, with 66% growth compared to the same period last year, underscores the effectiveness of the development model implemented at the start of 2024. Building on our expertise in spine surgery and the synergy between our product ranges, the combination of implant sales with the distribution of high-value medical equipment has significantly increased our sales across strategic markets. While the first half of 2024 was impacted by a slowdown in international activity, we are now reaping the benefits of our investments in the United States and are more convinced than ever of the strong growth potential of our solutions in this region. With the support of our key shareholder, Sanyou Medical, we intend to sustain this growth momentum by expanding our product offerings and continuing our innovation strategy.”

Fourth quarter 2024 growth of +81%

The Spine Implants activity achieved Q4 2024 revenue of €1.87 million, an increase of +16% compared to €1.61 million in Q4 2023.

The medical equipment distribution activity continued its growth, supported by the ongoing deployment of the Olea ultrasonic scalpel in France, internationally, and in the U.S. under the exclusive partnership with elliquence for the spinal endoscopy market. Revenue from this activity for Q4 2024 was €1.11 million, compared to €0.02 million in Q4 2023.

Activity in France grew by +8%, with revenue of €1.04 million for Q4 2024, compared to €0.96 million in Q4 2023. In the U.S., Q4 2024 revenue reached €1.13 million, up from €0.33 million in Q4 2023. Export activity in the rest of the world recorded €0.82 million in Q4 2024, compared to €0.36 million in the same period last year, representing growth of +132%, mainly driven by a recovery in orders from Europe and South America.

2024 Full-Year Revenue Growth of +26%

IMPLANET recorded full year revenue of €9.41 million in 2024, compared to €7.45 million in 2023.

Spine Implants activity generated €7.03 million in 2024, compared to €7.07 million in 2023. Meanwhile, the medical equipment distribution activity delivered €2.35 million in 2024, representing a growth of +676% compared to 2023.

Revenue in France grew by 17%, totaling €4.12 million. Revenue in the United States reached €2.57 million in 2024, up +86% from €1.38 million in 2023. Export activity in the rest of the world also increased by 6% to €2.72 million in 2024, compared to €2.56 million in 2023.

Cash Position

As of December 31, 2024, the Company had a cash position of €1.60 million.

As a reminder, the Company received €0.68 million related to the sale of the MADISON^TM activity, with the remaining balance of €0.17 million expected to be collected during the first half of 2025. Additionally, on December 5, 2024, IMPLANET announced the implementation of financing with Shanghai Pudong Development Bank (“SPD Bank”). This financing arrangement consists of a short-term working capital loan from SPD Bank, totaling RMB 15.2 million (around €2 million), for a 12-month term, repayable in full at maturity, without requiring collateral. The loan is intended for supplier payments and other operational expenses, with repayment guaranteed by Sanyou Medical.

Given this recent financing and cash flow projections based on current activity assumptions and anticipated commercial developments with Sanyou Medical for the 2024 and 2025 fiscal years, the Company believes it will be able to meet its operational financing needs for the next twelve months. Additionally, the Company continues to explore various financing options to accelerate the development of its activities and medium-term growth, as well as the implementation of payment facilities with the Sanyou Medical group.

Reminder of 2024 highlights

• Successful completion of the capital increase announced on January 4, 2024, raising €5.5 million through the issuance of 83,924,897 new shares;
• Appointment of Max W. Painter as Vice President and General Manager of IMPLANET’s US subsidiary;
• FDA clearance of the new Jazz Spinal System^TM hybrid posterior fixation range in the United States;
• Exclusive partnership signed for the distribution of the ultrasonic scalpel Olea for endoscopic spine surgery in the U.S. market.
• Financing of around €2 million with Shanghai Pudong Development Bank.

Upcoming financial event:

• 2024 Full-Year Results: March 4, 2025, after market close.

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributing medical technology equipment. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. In 2022, IMPLANET entered into a commercial, technological and financial partnership with SANYOU MEDICAL, China’s second largest medical device manufacturer. IMPLANET employs 43 staff and recorded a consolidated revenue of €9.4 million in 2024. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris.

For further information, please visit www.Implanet.com.

Disclaimer

This press release contains forward-looking statements relating to IMPLANET and its activities. IMPLANET believes these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the forecasts expressed in these forward-looking statements will be realized, as they are subject to risks, including those described in IMPLANET’s registration document filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 16, 2018, under number D.18-0337, as well as in the annual financial report as of December 31, 2023, both available on the Company’s website (www.implanet-invest.com). These statements are also subject to changes in economic conditions, financial markets, and the markets in which IMPLANET operates. The forward-looking statements in this press release are also subject to risks that are unknown to IMPLANET or not currently considered material. The occurrence of some or all of these risks could cause IMPLANET’s actual results, financial condition, performance, or achievements to differ significantly from those expressed in these forward-looking statements.

This press release is for informational purposes only and does not constitute, and should not be considered as constituting, an offer to sell or subscribe to, or a solicitation of an offer to purchase or subscribe to, IMPLANET’s securities in any country.

¹ Unaudited figures

Contacts

IMPLANET
Ludovic Lastennet, CEO

David Dieumegard, CFO

Tél. : +33 (0)5 57 99 55 55

investors@Implanet.com

NewCap
Investor Relations

Nicolas Fossiez

Tél.: +33 (0)1 44 71 94 94

Implanet@newcap.eu

NewCap
Media Relations

Arthur Rouillé

Tél.: +33 (0)1 44 71 94 94

Implanet@newcap.eu